Las Vegas, NV -- (SBWIRE) -- 09/21/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.EquityObserver.com issues a special report on the following stocks: Opko Health Inc.(NYSE:OPK), Eli Lilly & Co (NYSE:LLY), Lexicon Pharmaceuticals, Inc.(NASDAQ:LXRX) , Mylan Inc(NASDAQ:MYL)
Opko Health Inc.(NYSE:OPK) managed to keep its fall at -0.24% on above-normal volume of 6.39 million shares. The stock settled at $8.38 after floating in a range of $8.26 to $8.45. Its latest price was $8.38, reaching market capitalization of $3.38 million. Its 52-week range has been $4.05 to $10.00. Opko Health, Inc., a pharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics.
Has OPK Found The Bottom and Ready To Move Up? Find Out Here
Eli Lilly & Co (NYSE:LLY) traded up on a volume of 5.88million, higher than its standard daily volume. Shares have gained 0.13% to $53.39. Over the last twelve months, the stock has added 13.63% and faced a best price of $58.40. Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company?s neuroscience products treat major depressive disorders; schizophrenia.
For How Long LLY will Fight for Profitability? Read This Trend Analysis report
Lexicon Pharmaceuticals, Inc.(NASDAQ:LXRX) settled +1.97% higher at $2.33 on above-normal volume of 6.70 million shares during the last trading day. The stock has its 12-month high at $2.76 and 52-week low price was $1.55. It traded in a range of $2.55 to $2.36 during the last trading day. Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for human disease. Its portfolio of orally-delivered small molecule compounds in clinical development include LX4211 that has completed two Phase II clinical trials for the treatment of type 1 and type 2 diabetes.
For How Long LXRX Gloss will Attract Investors? Find out via this report
Mylan Inc(NASDAQ:MYL) saw its price gain on above-normal volume, as 5.43 million shares changed hands when compared with its average daily volume of 4.36 million shares. The stock was up 0.86% to $38.66. It has gained over the last 12 months, increasing 57.47% and marked new low $38.42. Mylan Inc. engages in the development, manufacture, marketing, licensing, and distribution of generic and branded generic pharmaceuticals, specialty pharmaceuticals, and active pharmaceutical ingredients (APIs) worldwide. It operates in two segments, Generics and Specialty.
Why Should Investors Buy MYL After The Recent Gain? Just Go Here and Find Out
About Equity Observer
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/ employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimerat: http://www.equityobserver.com/disclaimer-2/
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)